SCHEMBL5228784

SCHEMBL5228784

CC(C)(C)OC(=O)N1CCN2C(=O)CCC2(Cc2ccccn2)C1

nearest known ligand 0.44

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
USP30 Q70CQ3 1/20 0.44
GPR119 Q8TDV5 2/20 0.43
GRM5 P41594 1/20 0.41
PDE10A Q9Y233 1/20 0.41
POLB P06746 1/20 0.41
DTYMK P23919 1/20 0.40
CYP11B2 P19099 1/20 0.40
LMNA P02545 1/20 0.40
THRB P10828 1/20 0.40
ACHE P22303 1/20 0.39
OPRD1 P41143 1/20 0.38
OPRK1 P41145 1/20 0.38
CKS1B P61024 1/20 0.38
SKP1 P63208 1/20 0.38
SKP2 Q13309 1/20 0.38
KDM4E B2RXH2 1/20 0.38
ALDH1A1 P00352 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5230587 0.85 USP30 (0.43) USP30GPR119GRM5PDE10APOLB
SCHEMBL5230321 0.85 ACHE (0.42) USP30GPR119DTYMKCYP11B2LMNA
SCHEMBL5224568 0.81 GPR119 (0.42) USP30GPR119GRM5PDE10APOLB
SCHEMBL5225116 0.80 GPR119 (0.43) USP30GPR119GRM5PDE10APOLB
SCHEMBL5227965 0.78 GPR119 (0.41) USP30GPR119GRM5PDE10APOLB
SCHEMBL5226349 0.77 GRM5 (0.43) USP30GPR119GRM5PDE10APOLB
SCHEMBL5226358 0.77 GRM5 (0.43) USP30GPR119GRM5PDE10APOLB
SCHEMBL5226353 0.77 GRM5 (0.43) USP30GPR119GRM5PDE10APOLB
SCHEMBL31163752 0.77 GRM5 (0.43) USP30GPR119GRM5PDE10APOLB
SCHEMBL6693596 0.76 DTYMK (0.40) USP30GPR119GRM5PDE10APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1001970-B1 DIPEPTIDE DERIVATIVES AS GROWTH HORMONE SECRETAGOGUES PFIZER (US) 2007-03-07 EP disclosed
US-6953791-B2 Dipeptide derivatives PFIZER, INC. (US) 2005-10-11 US disclosed
US-6951850-B2 Dipeptide derivatives PFIZER, INC. (US) 2005-10-04 US disclosed
US-6924280-B2 Dipeptide derivatives PFIZER INC. (US) 2005-08-02 US disclosed
US-RE38524-E1 Dipeptide derivatives as growth hormone secretagogues PFIZER INC. 2004-06-01 US disclosed
US-20040009984-A1 Increasing levels of endogenous growth hormone, especially treating osterporosis, aging frailty or congestive heart failure CARPINO PHILIP ALBERT (US) 2004-01-15 US disclosed
US-20040006063-A1 Dipeptide derivatives CARPINO PHILIP ALBERT (US) 2004-01-08 US disclosed
US-20030216399-A1 Dipeptide derivatives CARPINO PHILIP ALBERT (US) 2003-11-20 US disclosed
US-6525047-B2 Which are growth hormone secretogogues and increase the level of endogenous growth hormone; treating osteoporosis, congestive heart failure, frailty associated with aging, obesity; accelerating bone fracture repair PFIZER INC. 2003-02-25 US disclosed
US-6433171-B1 FOR OSTEOPOROSIS AND/OR FRAILTY, CONGESTIVE HEART FAILURE, FRAILTY ASSOCIATED WITH AGING, OBESITY; ACCELERATING BONE FRACTURE REPAIR, ATTENUATING PROTEIN CATABOLIC RESPONSE AFTER A MAJOR OPERATION, REDUCING CACHEXIA AND PROTEIN LOSS PFIZER INC. 2002-08-13 US disclosed
US-6432945-B1 Dipeptide derivatives PFIZER INC. 2002-08-13 US disclosed
US-6429313-B2 Dipeptide derivatives PFIZER INC. 2002-08-06 US disclosed
US-20020042415-A1 Dipeptide derivatives CARPINO PHILIP ALBERT (US) 2002-04-11 US disclosed
US-20010041703-A1 Dipeptide derivatives CARPINO PHILIP ALBERT (US) 2001-11-15 US disclosed
US-6251902-B1 Dipeptide derivatives as growth hormone secretagogues PFIZER INC. 2001-06-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040009984-A1 Increasing levels of endogenous growth hormone, especially treating osterporosis, aging frailty or congestive heart failure GHSR, GHRHR, GIPR USP30 2135/4885GPR119 59/4885GRM5 2345/4885
US-20020042415-A1 Dipeptide derivatives GIPR, GHRHR, GHSR USP30 1692/4885GPR119 53/4885GRM5 894/4885
US-20010041703-A1 Dipeptide derivatives GIPR, GHRHR, GHSR USP30 1452/4885GPR119 55/4885GRM5 860/4885
US-20040006063-A1 Dipeptide derivatives GIPR, GHRHR, GHSR USP30 1467/4885GPR119 40/4885GRM5 1320/4885
US-20030216399-A1 Dipeptide derivatives GIPR, GHRHR, GHSR USP30 1692/4885GPR119 53/4885GRM5 894/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.